DaVita Inc. (DVA) Q4 2023 Earnings Call Transcript

DaVita HealthCare (DVA) came out with quarterly earnings of $1.87 per share, beating the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.11 per share a year ago.

DaVita forecast 2024 profit above Wall Street estimates on Tuesday on anticipated strong demand for its kidney dialysis services, sending its shares up 4.8% after the bell.

DENVER , Jan. 23, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Tuesday, February 13, 2024, at 5...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, MNDY, GTLB, LNW, SRPT.

The screen we explore today aims to find Zacks Rank #1 (Strong Buy) stocks that boast strong upward price momentum to help investors buy potential winners in January and throughout 2024.

After hitting new all-time highs in 2023, the S&P 500 is off to a slower start this year. The broad-based index is down 1.5% in the first week of trading.

Here are some dirt-cheap MedTech value stocks - DVA, GEHC, HOLX - which are expected to provide long-term gains.

DVA, LZ and MPTI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 22, 2023.

Tap top-ranked Otter Tail (OTTR), Rollins (ROL), DaVita (DVA) and NetEase (NTES) -- that come from top-ranked sectors too -- should realize the ongoing Fed-induced Santa Claus rally in 2023.

MPTI, LZ and DVA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 20, 2023.

DVA, EAT and EG made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 18, 2023.

LMB, DVA and PK made it to the Zacks Rank #1 (Strong Buy) growth stocks list on December 5, 2023.

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.